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The reaction of the redox-active ligand, Hpyramol (4-methyl-2-N-(2-pyridylmethyl)aminophenol) with
K2PtCl4 yields monofunctional square-planar [Pt(pyrimol)Cl], PtL-Cl, which was structurally
characterised by single-crystal X-ray diffraction and NMR spectroscopy. This compound unexpectedly
cleaves supercoiled double-stranded DNA stoichiometrically and oxidatively, in a non-speciﬁc manner
without any external reductant added, under physiological conditions. Spectro-electrochemical
investigations of PtL-Cl were carried out in comparison with the analogue CuL-Cl as a reference
compound. The results support a phenolate oxidation, generating a phenoxyl radical responsible for the
ligand-based DNA cleavage property of the title compounds. Time-dependent in vitro cytotoxicity
assays were performed with both PtL-Cl and CuL-Cl in various cancer cell lines. The compound
CuL-Cl overcomes cisplatin-resistance in ovarian carcinoma and mouse leukaemia cell lines, with
additional activity in some other cells. The platinum analogue, PtL-Cl also inhibits cell-proliferation
selectively. Additionally, cellular-uptake studies performed for both compounds in ovarian carcinoma
cell lines showed that signiﬁcant amounts of Pt and Cu were accumulated in the A2780 and A2780R
cancer cells. The conformational and structural changes induced by PtL-Cl and CuL-Cl on calf thymus
DNA and fX174 supercoiled phage DNA at ambient conditions were followed by electrophoretic
mobility assay and circular dichroism spectroscopy. The compounds induce extensive DNA degradation
and unwinding, along with formation of a monoadduct at the DNA minor groove. Thus, hybrid effects
of metal-centre variation, multiple DNA-binding modes and ligand-based redox activity towards
cancer cell-growth inhibition have been demonstrated. Finally, reactions of PtL-Cl with DNA model
bases (9-Ethylguanine and 5¢-GMP) followed by NMR and MS showed slow binding at Guanine-N7
and for the double stranded self complimentary oligonucleotide d(GTCGAC)2 in the minor groove.
Introduction
The serendipitous discovery of cisplatin and its extensive us-
age as an antitumour drug have initiated investigations in the
medicinal bioinorganic research ﬁeld towards numerous platinum
compounds. Multifactorial resistance (intrinsic or acquired) and
severe toxicity limit the prolonged administration of cisplatin,
having fuelled search for more potent metallodrugs with less
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systemic toxicity and internal resistance.1-3 The other platinum
anticancer drugs in clinical practise, or in current clinical trials, in-
clude platinum(II)-containing oxaliplatin, carboplatin, picoplatin
(JM473), nedaplatin (JM118), or redox-active platinum(IV)-
based satraplatin, tetraplatin and ormaplatin. Some of these
second or third generation compounds are stable through cell
metabolism,1,3,4 overcome the limitations by less systemic toxicity,
have better bio-availability and even display improved antitumour
activity.
Genomic DNA is most likely the main cellular target for
platinum drugs. Especially for cisplatin it has been demonstrated
that the major antitumour activity originates from intrastrand
crosslinks and the formation of DNA kinks.5 Therefore DNA
targeting drugs remain in the limelight and compounds acting
towards cancer cells selectively over healthy cells, are getting more
attention.6-10 The detailed investigation of cisplatin activation,
biotransformation, accumulation, coordinative binding, DNA
kinking and unwinding explains much of the antitumour activity
of this drug, originating from DNA damage.11 In recent literature,
there are some reports on ‘rule-breaker’ platinum compounds
which are highly active against tumour cells.12-14 These approaches
are focused on the design of compounds that may form adducts
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Fig. 1 Schematic structures of (a) Hpyramol, (b) its dehydrogenated form and (c) coordinated to a metal ion.
with DNA, differently than the classical cisplatin. The mode of
interaction of newly designed platinum compounds with target
biomolecules can be directed either via coordinative (interstrand
crosslinking), or via non-coordinative (intercalation, electrostatic,
groove-binding or hydrogen-bonding) interactions.15,16
The mono-substituted adduct of cisplatin with guanine has
proved to bemore genotoxic than the bis-guanine adducts.17 Based
on this evidence recently some interesting platinum complexes
have been synthesised and investigated which are classiﬁed as
‘monofunctional’ metallodrugs.18,19 These complexes possess a
single labile chloride and therefore after hydrolysis under phys-
iological conditions, they can form only mono-adducts with
DNA bases.20-22 Some of them exhibit interesting antiproliferative
activity with increasedDNAbinding afﬁnity. Themonofunctional
Pt-ACRAMTU series reported by Bierbach et al.18 for example
preferably target the DNA minor groove selectively, due to the
presence of a directing intercalator moiety.
Another approach to new antineoplastic metallodrugs could
be by making use of the well-known ‘chemical nucleases’. This
class of compounds cleave DNA in several pathways namely
(a) nucleobase oxidation, (b) phosphate ester hydrolysis and (c)
deoxyribose sugar oxidation. Such molecular scissors can cleave
DNA either by single or double strand breaks. The cellular
response from the living organelles against this damage is the
activation of multi-faceted repairing mechanisms such as base
excision repair, double strand break repair, crosslink repair and
nucleotide excision repair. The most efﬁcient chemical nucleases
contain transition metal ions, like the redox-active Cu, Fe, or
the redox-inactive Zn in their active sites. The classic examples
of this type of artiﬁcial nucleases used as antitumour drugs are
bleomycin and some of its metal-coordinated derivatives along
with [Cu(phen)2]+-based complexes.23
From our earlier work, a unique ligand 4-methyl-2-N-(2-
pyridylmethyl)aminophenol (Hpyramol)24 forming a compound
with CuCl2 (square planar [Cu(pyrimol)Cl], CuL-Cl) was
reported to cleave DNA oxidatively and catalytically without any
added reductant and to exhibit high to moderate antitumour
activity against selected cancer cell lines. The ligand alone is
also redox active in solution, but devoid of any DNA cleaving
or antineoplastic property towards most cancer cell lines on
its own. The protonated ligand form, Hpyrimol (HL), appears
to be formed by direct Hpyramol oxidation. Upon metal-ion
coordinationHpyramol undergoes oxidative dehydrogenation and
concomitant deprotonation to give the anionic ligand 4-methyl-
2-N-(2-pyridylmethylene)aminophenolate (pyrimol, L-). A
schematic diagram of the ligand, its several forms and
coordination patterns with metals is presented in Fig. 1.
When coordinated to redox-inactive Zn(II), the Hpyramol ligand
cleaves fX174 supercoiled phage DNA through a non-diffusible
ligand-based radical mechanism.25,26
These highly surprising results inspired us to react Hpyramol
with platinum(II), which is known to be redox-inactive under
physiological conditions; possibly a new potent DNA-targeting
anticancer drug might result, that could eventually induce cell
death by cleaving the cellular DNA efﬁciently and irreversibly.
Hence, the analogue PtL-Cl was synthesised and structurally
characterised by X-ray crystal structure determination, NMR
and other experimental techniques as reported below, to cor-
relate the DNA cleavage property and its in vitro cytotoxicity
towards cancer cell lines. The compounds, PtL-Cl and reference
CuL-Cl, were tested for the growth-inhibition of cultured tumour
cells. The total drug uptake in the selective cancer cells was
also measured. The compound PtL-Cl cleaved fX174 phage
DNA, as shown by agarose gel electrophoresis, at more than
stoichiometric ratio. High resolution PAGE (PolyAcrylamide Gel
Electrophoresis) gel experiments were performed to observe any
sequence-speciﬁc DNA cleavage by PtL-Cl. As DNA is the most
expected target here, PtL-Cl was allowed to interact with calf
thymus DNA and fX174 supercoiled phage DNA. Circular
dichroism was used to monitor any conformational changes
on its binding. The reactions of PtL-Cl with the model bases
9-ethylguanine and 5¢-GMP were followed by 1H and 195Pt
NMR to investigate the stability of the mono-adduct with the
guanine residue on DNA. The compound PtL-Cl was reacted
with self-complementary d(GTCGAC)2 oligonucleotide to detect
any solution structural changes upon interaction. A detailed
spectro-electrochemical analysis and comparison of the redox
behaviour of PtL-Cl with CuL-Cl and Hpyrimol were performed
to obtain support for the ligand-based radical-induced oxidative
DNA damage caused by PtL-Cl.
Experimental section
Materials
9-Ethylguanine (9-EtG) and Guanosine-5¢-monophosphate
(5¢-GMP) were purchased from Sigma-Aldrich B.V. The fX174
supercoiled phage DNA used for DNA cleavage studies was pur-
chased from Invitrogen Life Technology (0.25 mg/mL).Deuterated
solvents used for NMR experiments were also purchased from
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Sigma-Aldrich. K2PtCl4 was used from a generous loan scheme
by Johnson-Matthey (Reading, U.K.). The ligand Hpyramol
(4-methyl-2-N-(2-pyridylmethyl)aminophenol) was synthesised in
a single-step reaction as reported in the literature.24 The solvents
used in the syntheses were purchased from Biosolve (AR grade)
and used without further puriﬁcation.
Syntheses
[Pt(pyrimol)Cl], (PtL-Cl). Anaerobic ethanolic solutionof the
precursor ligand, Hpyramol (51.6 mg, 0.24 mmol) was added in
the dark drop-wise to an aqueous solution of K2PtCl4 (100 mg,
0.24 mmol) and stirred at 50 ◦C for 24 h. The reaction mixture was
ﬁltered while warm and the ﬁltrate was evaporated to 5 mL under
reduced pressure.Adeep green precipitatewas obtained by cooling
down this concentrated ﬁltrate at 4 ◦C overnight. The precipitate
was washed with cold ethanol (3 ¥ 2 mL), then with diethyl ether
(3 ¥ 5 mL) and dried under suction in the dark. Yield: 65.98 mg
(62 %). Elemental analysis for C13H11N2OClPt: C, 35.34; H, 2.50;
N, 6.34 (Calcd.), C, 35.25; H, 2.42; N, 6.10 (Expt.). The green
precipitate was characterised as Pt(pyrimol)Cl by 1H, 13C, 195Pt,
2-D COSY and 1H-13CHETCOR spectroscopy. 195Pt NMR shows
a single peak at -2326 ppm (in DMSO-d6) and -2322 ppm (in
DMF), corresponding to a PtN2OCl coordination environment.
Single crystals suitable for X-ray diffraction were grown in the
dark from a concentrated DMSO solution in the NMR tube.
[Cu(pyrimol)Cl], (CuL-Cl). The compound CuL-Cl was re-
produced by following the method already reported.26 A deep-
red crystalline powder was characterised by elemental analysis,
infrared and EPR spectroscopy. A good match with the literature
data was observed.
X-ray crystal structure determination of PtL-Cl
Single crystals suitable for X-ray diffraction were obtained directly
from an NMR tube which contained a concentrated DMSO-d6
solution of PtL-Cl and was kept at ambient temperature in the
dark. X-ray intensities were measured on a Nonius KappaCCD
diffractometer with a rotating anode (graphite monochromator,
l= 0.71073 A˚) at -123 ◦C. Data were integrated with EvalCCD27
using an accurate description of the experimental setup for the
prediction of the reﬂection contours. Absorption correction and
scaling were performed with the program SADABS.28 The struc-
ture was solved by application of automated Patterson methods
(DIRDIF-9929). The reﬁnement was performed with SHELXL-
9730 against F2 of all reﬂections. Non-hydrogen atoms were reﬁned
with anisotropic displacement parameters. All hydrogen atoms
were located in difference-Fourier maps and reﬁned with a riding
model. Geometry calculations and checking for higher symmetry
were performed with the PLATON program.31 Further details of
the molecular structure of PtL-Cl are given in Table 1 and in
Supplementary Information (Table S1).†
NMR experiments
The one-dimensional (1H and 13C) and two-dimensional COSY
and HETCOR spectra were recorded on a 600 MHz Bruker
DPX600 spectrometer at ambient temperature (24 ◦C) in DMSO-
d6. The 195Pt spectra were recorded on a 300 MHz Bruker
Table 1 Crystal data and structure reﬁnement for the compound PtL-Cl
formula C13H11ClN2OPt
formula weight 441.76
crystal colour dark red
crystal size [mm3] 0.21 ¥ 0.03 ¥ 0.03
T [K] 150(2)
l [A˚] 0.71073
crystal system triclinic
space group P1¯ (no. 2)
a [A˚] 7.1447(3)
b [A˚] 8.5058(3)
c [A˚] 10.2432(3)
a [◦] 83.230(2)
b [◦] 76.509(1)
g [◦] 87.059(2)
V [A˚3] 600.91(4)
Z 2
Dx [g cm-3] 2.442
m [mm-1] 11.884
abs. corr. multi-scan
abs. corr. range 0.36–0.70
(sin q/l)max [A˚-1] 0.65
reﬂections (collected/unique) 9030/2743
parameters/restraints 164/0
R1/wR2 [I>2s(I)] 0.0246/0.0492
R1/wR2 [all reﬂ.] 0.0355/0.0518
R(int) 0.0403
S 1.050
rmin/max [e A˚-3] -1.05/0.94
spectrometer with a 5mmmulti-nucleus probe at 24 ◦C inDMSO-
d6 and non-deuterated DMF solvents. For 195Pt NMR, Na2PtCl6
was used as external reference set at d = 0 ppm.
Biological studies
(a) Cells and culture conditions. The 100 mm culture and
micro-well plates were received from NUCLON (Roskilde,
Denmark). MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetra-
zoliumbromide] was purchased from Sigma-Aldrich B.V. The
human ovarian carcinoma cell lines, cisplatin sensitive (A2780)
and cisplatin resistant (A2780R), were generous gifts from
Dr. J. M. Perez (Universidad Autonoma de Madrid, Spain).
The mouse leukemia cell lines, cisplatin sensitive (L1210/0) and
cisplatin resistant (L1210/2), were used for the MTT assay as
well. The cells were grown as monolayers in Dulbecco’s Modiﬁed
Eagle’sMedium (DMEM) supplementedwith 10% fetal calf serum
(Gibco, Paisley, Scotland), penicillin (100 units/mL; Dufecha,
The Netherlands) and streptomycin (100 mg/mL; Dufecha, The
Netherlands). During the culture period the cells grew partly in
suspension and partly adhered to the ﬂask wall.
(b) Cytotoxicity assays.
MTT assay. The cell survival was evaluated by a typical MTT
colorimetric method32 albeit slightly modiﬁed. Cells were plated
onto 96-well sterile plates (Corning Co.) in 100 mL of medium at
a density of 2 ¥ 103 cells per well and incubated for 48 h at 37 ◦C
in a 7% CO2 containing incubator. The compound was added at
six different concentrations. The ﬁnal concentrations ranged from
0.4 mM to 90 mM. As the stock solution of PtL-Cl was made
in DMF, in order to see the solvent effect, DMF was used as
the blank. For comparison the starting ligand (Hpyramol) and
cisplatin were tested in the same plate and the stocks in both cases
were made in DMF. In addition, for comparison with the reported
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value of IC50 for cisplatin (in water) the latter was also tested as
in a typical aqueous solutions. A freshly prepared MTT solution
(5 mg/mL) in PBS buffer was added to each well (50 mL per well)
after 48 h of incubation. The plates were then again incubated at
37 ◦C for 3 h.All the supernatant liquidwas removed very carefully
without disturbing the blue crystals stuck at the bottom of the
plates. The MTT was metabolised by the mitochondrial reduction
of the living cancer cells and transformed to a blue formazan
product. These crystals were dissolved in 100 mL DMSO per
well and were shaken carefully until the crystals were completely
dissolved to give a purple solution. The absorbance of each
well was determined at 590 nm by using a Model 550 Bio-Rad
microplate reader. All the tests were performed in quadruplicate
for each cell line. The IC50 values were calculated from the curves
drawn by plotting % cell survival versus compound concentration
(in mM) using the program Graphpad Prism, version 3.0, 2000.16
The IC50 value indicates the amount of drugneeded for 50%growth
inhibition of the cancer cells relative to untreated (drug-free cancer
cells).
SRBassay. The cytotoxicities of PtL-Cl, CuL-Cl and the ligand
Hpyramolwere analysed using themicroculture sulforhodamineB
(SRB) test,33 carried out commercially with TEVA-Pharmachemie
(Haarlem, The Netherlands). Human tumour cell lines analysed
were WIDR, IGROV, M19-MEL, A498 and H226, which belong
to the currently used anti-cancer screening panel of the National
Cancer Institute, USA34 with additional two breast cancer cell
lines, i.e., MCF-7 (containing estrogen and progesterone recep-
tors) and EVSA-T (lacking both hormone receptors). All cell lines
were maintained in a continuous logarithmic culture in the RPMI
1640 medium with the Hepes buffer and phenol red. The medium
was supplemented with 10% FCS, penicillin (100 IU/mL) and
streptomycin (100 mg/mL). The cells were mildly trypsinised for
passage and for the use in the experiments. Trypsinised tumour
cells (150 mL, containing 2 ¥ 103 cells/well) were pre-incubated
for 48 h at 37 ◦C in 96-well ﬂat-bottom cell culture plates. The
tested compounds were added in a three-fold dilution series up
to and including 62.5 mg/mL. After 7 days the cells were ﬁxed
with 10% TCA in the PBS buffer and incubated at 4 ◦C for
1 h. After three times washing with water the cells were stained
for 15 min with 0.4% SRB in 1% acetic acid. Subsequently the
cells were washed with 1% acetic acid, air-dried and the bound
stain dissolved in 150 mL 10 mM Tris-base (unbuffered). The
value of A540 was assessed using an automated microplate reader
(Labsystems Multiskan MS). Data were used for concentration-
response curves and ID50 values using Deltasoft 3 software
(Biometallics Inc., Princeton, NJ, USA).16 Subsequent conversion
of units provided the IC50 values for all samples tested.
(c) Cellular uptake experiments. Cells of the A2780 and
A2780R cell lines were plated in sterile 6-well plates in 5 mL
of Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) at a density
of 1 ¥ 105 cells per well and incubated for 48 h. The cisplatin,
CuL-Cl and PtL-Cl were added to the plates at the ultimate
concentration of 200 nM, and incubated for 2, 6 and 24 h.
Afterwards the cells were washed twice with 5 mL PBS per well
and triton (lysis buffer) was added (350 mL per well) to lyse the
cells. After transferring the pellet to Eppendorf tubes, 10% SDS
(100 mL per well) and Proteinase K (20 mg/mL and 1 mL per
well) were added. Then the viscous pellets were incubated at 55 ◦C
for 30 min and 1.5 mL 20% HNO3 was added. After shaking for
45 min the samples were measured by Varian Vista-MPX charge-
coupled simultaneous ICP-OES (Inductively Coupled Plasma
Optical Emission Spectroscopy) to estimate of % Pt and % Cu
taken up by the cancer cells. To compare the accumulation of
Pt-moieties inside the cisplatin sensitive, A2780 cells, time-
dependent uptake studies were also performed for PtL-Cl at 2 h
intervals for up to 24 h. The active concentration of PtL-Cl used
for the time-dependent measurement was 50 mM.
(d) DNA cleavage studies. fX174 supercoiled phage DNA
was purchased from Invitrogen Life Technologies and stored at
-20 ◦C.A typical reactionmixture, containing supercoiled plasmid
DNA and PtL-Cl in a 10 mM phosphate buffer at pH 7.2, was
incubated at 37 ◦C for 2 h (with or without additives, or without
any external reductant). After the incubation period, the reaction
was quenched by keeping the samples at -20 ◦C, followed by the
addition of loading buffer (bromophenol blue, xylene cyanol, and
25% ﬁcoll). This was then loaded on a 0.8% agarose gel containing
ethidium bromide (2.54 mM in the gel as well as in the buffer). The
gels were run at a constant voltage of 80V for 60-90min in theTBE
buffer containing ethidium bromide. After washing with distilled
water, the gels were visualised under a UV transilluminator and
the bands were documented and quantiﬁed using a BioRad Gel
Doc 1000 apparatus interfaced with a computer.
(e) High resolution denaturing gel electrophoresis.
Preparation of oligonucleotides and PAGE. For the high res-
olution analysis of the DNA cleavage process, a double-
stranded oligonucleotide was used. The synthetic procedure to
prepare this type of oligonucleotides has a coupling efﬁciency
of 97-99%. Therefore, in each step, a short side product is
formed, whose intensity on the electrophoresis gel is asso-
ciated with the coupling efﬁciency (a 99% efﬁciency implies
that 1% side product is present, 97% gives 3% side product
and so on). Consequently, the electrophoresis reveals a ladder-
like pattern, with a weak band at each nt (nucleotide) po-
sition. This is ideally suited for the detailed analysis of the
cleavage mechanism. A 54 nt oligonucleotide FNA1 (DNA se-
quence 5¢-GATCCTGGTGGAGCTAAGCGGGATCGAACC-
GCT-GACCTCTTGCTTGCATAGCAA-3¢) was radiolabelled
with [g -32P]ATP (MP Biomedicals) using T4 polynucleotide
kinase (Fermentas) as indicated by the supplier, and pu-
riﬁed over S200 spin columns (GE healthcare), effectively
removing all products up to 15 nt.35 Duplex DNA was
obtained by annealing the 10 mM [32P]-labelled FNA1
with an equimolar amount of oligonucleotide FNA2 (5¢-
AGCGCTTGCTATGCAAGCAAGAGGTCAGCGGTTCG-
ATCCCGCTTAGCTCCACCA-3¢) in 250 mM NaCl solution at
70 ◦C for 2 min, followed by slow cooling to ambient temperature.
On either side, the probe has 5 nucleotides of a single-stranded
region at the 5¢ end (underlined in the oligonucleotides). For
copper-induced cleavage experiments, the FNA1/2 duplex DNA
was incubated at a concentration of 100 mM bp with 20 mM
of compound, CuL-Cl at 37 ◦C. At indicated time intervals
(0-60 min), samples were taken and quenched with an equal
volumeof stop solution (90% [v/v] formamide and 50mMH4edta)
at -20 ◦C.26 DNA was incubated at a concentration of 100 mM bp
with 50 mM and 200 mM of platinum compound, PtL-Cl at 37 ◦C
at indicated time intervals (0-150 min). Samples were separated
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by high resolution denaturing PAGE (15%) and visualised by
phosphor imaging (Bio-Rad).
Enzymatic religation. pUC19 plasmid DNA was treated with
PtL-Cl, CuL-Cl, or with the restriction enzyme BamH1, without
any reductant, at 37 ◦C and at pH 7.2. DNA samples were puriﬁed
over QIAquick PCR puriﬁcation columns (Qiagen) and used for
religation experiments. The ligation reaction was performed in a
20 mL volume using 50 ng of the digested DNA products with
2 units of T4 DNA ligase (Fermentas) for 16 h at 16 ◦C.
(f) Circular dichroism. Circular dichroism spectra were
recorded at 37 ◦Cusing a Jasco J-815 spectropolarimeter equipped
with a Jasco PTC-423 S Peltier temperature controller. The
scanning rate was 100 nm/min with a response time 1 s. Spectra
were recorded at standard sensitivity (100 mdeg) with a data-pitch
of 0.5 nm in continuousmode. The scanning rangewas 320-220 nm
and all the spectra were average of four consequent accumulations.
The cuvettes used were 2 mm Quartz Suprasil precision cells
(Hellma). The baseline was corrected using 10 mM phosphate
buffer as a reference. Volume of sample in the cuvettes was kept
constant at 700 mL.
A typical sample containing DNA (Calf thymus DNA or
supercoiled fX174 phageDNA) andmetal compounds (PtL-Cl or
CuL-Cl) in phosphate buffer was incubated at 37 ◦C and the CD
spectra were collected at the given time intervals. As references,
cisplatin and the free ligand, Hpyramol were also interacted with
DNA under similar conditions as followed for PtL-Cl or CuL-Cl.
(g) Electrochemical studies. Cyclic voltammetry of 1 ¥ 10-3 M
PtL-Cl in a single-compartment cell was carried out with an Au-
tolab PGstat10 potentiostat (Eco Chemie) controlled by GPES4
software, or with anEG&GPARModel 283 potentiostat operated
with the PARPower CVR© software. TheDMF solutions contained
10-1 M Bu4NPF6 as the supporting electrolyte. The three-electrode
system consisted of a carefully polished Pt disk working electrode,
a Pt auxiliary electrode, and an Ag/AgCl reference electrode.
The voltammetric response of the standard ferrocene/ferrocenium
(Fc/Fc+) couple was found in this system at +0.43 V vs Ag/AgCl.
The air-tight UV-Vis spectroelectrochemical cell employed for the
in situ oxidation of 2 ¥ 10-3 M of PtL-Cl and the ligands Hpyramol
and Hpyrimol at room temperature, has been described in detail
elsewhere.36 The electrode potential was controlled during the in
situ electrolyses by a PA4 potentiostat (EKOM, Polna´, Czech
Republic). UV-Vis spectra were recorded with a HP 8453 diode
array spectrophotometer.
(h) Reactions with model bases.
NMR experiments. The compound PtL-Cl (4mM)was allowed
to react with 9-ethylguanine and 5¢-GMP at different stoichiomet-
ric ratios. The solvents used were DMSO-d6 (for 9-Ethyl guanine)
and DMSO-d6/D2O mixture (for 5¢-GMP) studies in an NMR
tube. The reactants were mixed prior to the measurements, where
the time interval between the mixing and recording of the ﬁrst
spectrum was maximum 15 min The experimental temperature
was maintained at 37 ◦C (for pseudo-physiological conditions) for
overnight series 1HNMRexperiments. After 14 h the sampleswere
kept in a water bath for maximum 30 days at 37 ◦C and spectra
were recorded at different time-intervals. 195Pt NMR spectra were
recorded after 24 and 48 h to observe the changes in the Pt
coordination sphere.
ESI-MS measurements. All the spectra were recorded on a
Finnigan AQA instrument equipped with electrospray inter-
face (ESI). The reactions between PtL-Cl and model bases
(9-ethylguanine and 5¢-GMP) were followed by ESI-MS at time
intervals of max 15 min up to 3 h, and also after 24 h. The solvents
used were DMSO and a DMSO/H2O 1:1 mixture (v/v) for the
two model bases, respectively. The samples from the NMR tubes
were also directly used to identify reaction products.
(i) NMRSolution studies with d(GTCGAC)2. 1HNMRspectra
were recorded on a Bruker 600 MHz spectrometer. The temper-
ature was varied from 7 to 47 ◦C to determine the fast exchange
kinetics. Afterwards the 2-DNOESY spectra were recorded by the
method37 of States et al.using 2048datapoints in t2 for 256 t1 values
with a pulse repetition delay of 2 s at 17 ◦C or 27 ◦C. DQF-COSY
experiments were also accumulated using 2048 data points in t2 for
256 t1 valueswith a pulse repetition delay of 2 s. Spectra recorded in
90% H2O and 10% D2O were collected using the WATER GATE
solvent suppression technique of Piotto et al.38 1H chemical shifts
are relative to (tetramethylsilyl)propionic acid (TSP) as internal
standard. Typical samples contained 1mMd(GTCGAC)2 duplex,
1 or 2 mM PtL-Cl, 20 mM NaCl in D2O, and 10 mM phosphate
buffer (pH = 7) in 0.5 mL of H2O.
Results and discussion
Synthesis
The chemical synthesis of PtL-Cl is straightforward and success-
fully completed in a single step. K2PtCl4 and the ligand Hpyramol
are reacted in equimolar ratio to yield the compound PtL-Cl as a
crystalline green powder. The spectroscopic and elemental analy-
ses prove the formation as PtL-Cl. The 195Pt NMR shows a single
peak (at-2326ppm),which is in the region common forPtN3Oand
PtN3Cl coordination environments.39,40 No evidence is observed
of any fold-back signal, so the single peak can be attributed to a
PtN2OCl environment. No attempts were undertaken to study the
stepwise dehydrogenation of Hpyramol in the presence of K2PtCl4
under anaerobic conditions or otherwise, as the reactions had
always been performed under aerobic conditions. The ESI-MS of
PtL-Cl in DMSO solution shows a major peak at m/z = 484.32,
which corresponds to the cation [Pt(pyrimol)(dmso)]+ formedafter
the solvolysis of relatively labile chloride ligand by DMSO. The
C,H,N elemental analysis also ﬁts with the elemental percentage
calculated for PtL-Cl.
Crystal structure description
Needle shaped single crystals of PtL-Cl were obtained by slow
evaporation of a concentratedDMSO-d6 solution in anNMRtube
at ambient temperature under exclusion of day light. The crystal
structure shows the starting ligand Hpyramol to dehydrogenate
and coordinate to Pt(II) through the N2O-binding motif, which
results in an almost square-planar geometry with cis angles be-
tween 81.74(15)◦ and 99.14(11)◦ (Fig. 2). The molecular structure
is quite similar to the reported CuL-Cl,26 but the packing in
the crystal lattice is completely different, apparently due to the
co-crystallised H2O in CuL-Cl. The planar PtL-Cl molecules
are stacked on top of each other in an anti-parallel fashion
in the direction of the crystallographic a-axis (Fig. S1†) with
10850 | Dalton Trans., 2009, 10846–10860 This journal is © The Royal Society of Chemistry 2009
Fig. 2 Displacement ellipsoid plot of PtL-Cl in the crystal (50%
probability level).
intermolecular Pt ◊ ◊ ◊Pt distances of 5.0418(3) and 4.7540(3) A˚.
The corresponding interplanar distances are 3.43 and 3.31 A˚,
respectively. Besides this molecular stacking no other strong
intermolecular interactions could be detected. This observation is
understandable, as no strong hydrogen bond donors are present.
Consequently the long dimension of the needle shaped crystals
corresponds to the crystallographic a-axis. In CuL-Cl there is also
anti-parallel molecular stacking in the a-direction, with Cu ◊ ◊ ◊Cu
distances of 5.1647(3) and 6.1325(3) A˚ and interplanar distances
of both 3.34 A˚; however, the stacks are linked with each other
by intermolecular hydrogen bonds involving the co-crystallised
H2O molecules. More relevant crystallographic data for PtL-Cl
are available in the Supporting Information (Tables 1 and S1†).
Cytotoxicity assays
MTT assay. The in vitro cytotoxicity tests were performed
for human ovarian carcinoma and mouse leukemia cancer cell
lines (See Experimental for details). The IC50 values (in mM) are
summarised in Table 2with their respective standard deviations. In
ovarian carcinoma cell line (both cisplatin sensitive and resistant)
the IC50 values for PtL-Cl are very high (22.4 and 43.6 mM,
respectively), which indicates its low activity when compared to
leukemia cell line (8.1 and 27.5 mM, respectively). The IC50 values
in cisplatin resistant cell lines are higher than in cisplatin sensitive
cell lines, which is generally observed. In leukemia cell lines
PtL-Cl overcomes cisplatin resistance to some extent as evident
from theRFvalue of 3.4. Therefore, the compoundPtL-Cl is active
towards leukemia cell line and moderately active towards ovarian
carcinoma cell lines. CuL-Cl shows very high antiproliferative
properties in these four cell lines, as in all cases the IC50 values are
similar or even lower than the IC50 values for cisplatin itself and this
compound overcomes cross-resistance to cisplatin in both types
of cancer cell lines. On the other hand, free Hpyramol is active in
ovarian carcinoma cell lines, but in leukemia cell lines it exhibits
almost no activity. It is therefore evident that the cytotoxicity
proﬁle has changed signiﬁcantly after coordination with Pt(II) or
Cu(II). For comparison cisplatin was also tested after dissolution
in DMF, similarly as PtL-Cl and free ligand. It is evident from
the table that the IC50 values calculated for cisplatin (in DMF)
are quite different than the IC50 values for cisplatin in aqueous
solution.This observation indicated that, althoughDMF is known
as a weakly coordinating solvent, in some cases it can also act like
a coordination solvent (replacing coordinated chloride) and the
solvated species can result in a different biodistribution.
The effect of different times of incubation on the activity
towards cell lines has also been investigated. The cytotoxic activity
of PtL-Cl was found to be reduced with longer incubation time.
The IC50 values are increased by 2-fold (A2780), 3-fold (A2780R),
18-fold [L1210(0)] and 4-fold [L1210(2)], respectively. When the
incubation time is shorter, CuL-Cl exhibits a high activity, i.e.
as high as cisplatin, whereas longer incubation times repress the
activity. The results are shown in Table 2 for incubation times
48 h and 120 h. The loss of activity in resistant cell lines, A2780R
and L1210(2) is more signiﬁcant than in the case of the cisplatin
sensitive, A2780 and L1210(0) cell lines. The prolonged incubation
time reduced the activity of CuL-Cl up to eighteen to twenty times
in cell lines tested. The differences can be explained by either
by increased efﬂux, or by increased cellular assimilation of the
biologically relevant metal ion, Cu(II), in CuL-Cl. In case of
cisplatin and PtL-Cl, the results can be explained also by enhanced
efﬂux and slower cellular uptake.
SRB assay. Seven human tumour cell lines with different
origin were used to test the activity of PtL-Cl and CuL-Cl. For
cisplatin and CuL-Cl stock solutions were made in MilliQ water,
while for PtL-Cl, DMSO is used to make the stock solution. The
results are summarised inTable 3. The activity proﬁle clearly shows
a dependence on the time of incubation. For all cell lines, the
activity of cisplatin was found higher with prolonged incubation.
The activity of cisplatin after 120 h of incubation was six to
twelve times higher than after 48 h of incubation. This difference
Table 2 IC50 values in mM of samples against human ovarian carcinoma and mouse leukaemia cancer cell lines (cisplatin sensitive and resistant) after
48 h and 120 h of incubation
Samples Time (h) A2780 A2780R RFa L1210(0) L1210(2) RF
Cisplatin (water) 48 2.9 ± 0.2 13.1 ± 0.2 4.5 4.0 ± 0.3 24.2 ± 0.2 6.1
Cisplatin (DMF) 8.6 ± 0.4 17.2 ± 0.3 2.0 5.6 ± 0.2 14.6 ± 0.7 2.6
Hpyramol (DMF) 15.0 ± 0.3 13.8 ± 0.3 0.9 >>50 >50 —
PtL-Cl (DMF) 22.4 ± 0.4 43.6 ± 0.5 1.9 8.1 ± 0.3 27.5 ± 0.3 3.4
CuL-Cl (water) 3.4 ± 0.2 8.3 ± 0.6 2.4 3.6 ± 0.2 10.3 ± 0.3 2.9
Cisplatin (water) 120 1.1 ± 0.2 21.9 ± 0.7 19.9 3.1 ± 0.6 39.7 ± 0.4 12.8
PtL-Cl (DMF) 38.8 ± 0.2 120.9 ± 0.8 3.1 42.2 ± 0.4 121.6 ± 0.8 2.9
CuL-Cl (water) 63.9 ± 0.5 158.8 ± 0.7 2.5 62.8 ± 0.4 153.8 ± 0.6 2.4
a The Resistance Factor (RF) is deﬁned as the relative ratio of IC50 values in resistant and sensitive variety of similar cell lines, e.g., A2780R/A2780 or
L1210(2)/L1210(0), respectively. IC50 value is deﬁned as the amount of a compound needed to inhibit 50% of cell growth. The deviations are incorporated
with the values.
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Table 3 IC50 values in mM of samples against seven human tumour cell lines after 48 h and 120 h of incubation
Samples Time (h) A498 EVSA-T H226 IGROV M19-MEL MCF-7 WIDR
Cisplatin 48 8.2 17.2 10.4 3.0 9.7 16.3 21.1
PtL-Cl 51.5 26.2 69.5 24.8 59.3 31.5 50.9
CuL-Cl 33.4 1.3 29.4 18.6 2.2 21.4 36.2
Cisplatin 120 6.2 2.5 2.1 0.74 2.3 2.7 1.8
PtL-Cl 8.8 38.4 56.6 45.2 54.4 27.4 62.7
CuL-Cl 4.3 10.6 11.5 17.2 1.5 10.6 29.9
can be explained by higher accumulation over a longer time-period
and reduced efﬂux. In the case of PtL-Cl, there is no smooth
trend of change. The activity of PtL-Cl, in the A498 cell line, was
increased by six folds after 120 h (IC50 values range 51.5 mM to
8.8 mM) incubation. In the H226 and MCF-7 cell lines the activity
of PtL-Cl was found to be enhanced as well. For other cell lines
no prominent effect of time-period of incubation was noticed.
The signiﬁcant change in activity was also observed in the case of
CuL-Cl. In the A498, H226 and MCF-7 cell lines the activity
of CuL-Cl was found increased by seven, two and two times,
respectively. In the other three cell lines, i.e. IGROV, M19-MEL
and WIDR, the activity of CuL-Cl was also found increased,
but to a smaller extent. A completely contrasting behaviour was
observed in the EVSA-T cell line, where the activity of CuL-Cl
is repressed by almost eight times upon longer incubation times.
Apparently the changes in activity proﬁle are strongly dependent
on the time of incubation and consequently on uptake and efﬂux,
deactivation and interaction with cellular targets.
The variability of the in vitro cytotoxicity test depends on the
cell line used and the serum applied. With the same batch of
cell lines and the same batch of serum the interexperimental CV
(coefﬁcient of variation) is 1-11% depending on the cell line, and
the intraexperimental CV is 2-4%. These values may be higher
when using other batches of cell lines and/or serum.
Uptake of PtL-Cl and CuL-Cl in ovarian carcinoma cells
In order to explain the huge difference in the cytotoxicities
(PtL-Cl and CuL-Cl), uptake studies have been performed in
A2780 and A2780R cell lines. The amount of Pt or Cu which
were taken up by both cisplatin sensitive and resistant ovarian
carcinoma is shown in Figs. 3a and 3b, respectively. In the
A2780 cell line the platinum compounds, both cisplatin and
PtL-Cl,were accumulated increasingly inside the cellswith gradual
increase in incubation time,whereas theCu-compound,CuL-Cl, is
accumulated at its highest concentration after 24 h incubation. The
amount of Pt accumulated inside the A2780 cells is similar when
compared to cisplatin, which is not at the same line with its lower
cytotoxicity. The Cu-accumulation does not follow any smooth
trend as after 6 h there is some excretion and after 24 h a signiﬁcant
amount of Cu can be detected. This extent of accumulation can
easily explain the high activity of compound CuL-Cl in ovarian
carcinoma cell lines.
In resistant cell lines the same trend was followed by the
platinum compounds, but maximum accumulation of Cu was
found to be achieved after 24 h, after some initial excretion
at 6 h. As the resistant cell lines are obtained after multiple
exposures of cell lines to cisplatin over a certain time period,
the uptake of Pt-compounds is expected to be lower than for
the sensitive counterpart. The data observed for cisplatin are in
agreement with the expected value, even though PtL-Cl exhibits
a different behaviour. Although a signiﬁcant amount of platinum
derived from the compound PtL-Cl was detected and shown to be
accumulated in a higher amount compared to cisplatin in the cell,
the low cytotoxicity cannot be directly related. The deactivation
by cellular platinophiles can be the most plausible explanation.
On the contrary, Cu is more abundant in the physiological
environment; the cellular uptake for Cu-compound would be
Fig. 3 Amount of Pt/Cu accumulated inside (a) A2780 and (b) A2780R cell-lines at different incubation times from cisplatin, PtL-Cl and CuL-Cl.
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Fig. 4 a. Agarose gel electrophoresis of fX174 supercoiled phage DNA incubated with PtL-Cl at 37 ◦C, in the phosphate buffer at pH = 7.2. Lane 1,
DNA blank (20 mM in base pairs), lane 2, 20 mM DNA + 10 mM of PtL-Cl, lane 3, 20 mM DNA + 20 mM of PtL-Cl, lane 4, 20 mM DNA + 50 mM of
PtL-Cl, lane 5, 20 mM DNA + 100 mM of PtL-Cl, lane 6, 20 mM DNA + 200 mM of PtL-Cl, lane 7, 20 mM DNA + 10 mM of PtL-Cl + 20 mM ascorbic
acid, lane 8, 20 mM DNA + 20 mM ascorbic acid, lane 9, 20 mM DNA + 10 mM of PtL-Cl +20 mM TEMPO, lane 10, 20 mM DNA + 20 mM TEMPO.
b. Agarose gel electrophoresis of the oxidative cleavage reaction of fX174 supercoiled phage DNA (20 mM in base pairs) with PtL-Cl (100 mM) without
reductant after an incubation time of 2 h at 37 ◦C in the phosphate buffer at pH = 7.2 (lanes 10 and 11), in the presence of the following species: for lane
1, 200 mM NaN3; lane 2, DMSO; lane 3, 0.5 U of superoxide dismutase; lane 4, 100 mM distamycin; lane 5, ethanol; lane 6, D2O; lane 7, 350 mM NaCl;
lane 8, reaction performed under an argon atmosphere; lane 9, reaction with exclusion of light.
expected to be faster than for the toxic metal compounds, cisplatin
and PtL-Cl. The uptake or accumulation pathway of the CuL-Cl
is most likely to be different from that of platinum compounds, as
relatively higher amounts of Cu can be detected.
In order to quantify the amount of platinum accumulated inside
the A2780 cells with a certain time interval (2 h), a separate
experiment was performed with 50 mM of PtL-Cl. The maximum
accumulation observed after 18 h of incubation but the time-scale
of cancer cell-cycle is around 24 h. The changes in the amount of
platinumaccumulated inside the cells donot followa speciﬁc trend,
which may be interesting to be studied in more details. In Fig. S2†
the concentration of platinum inside the cell versus incubation time
has been plotted to draw a correlation of the uptake-accumulation
and cytotoxicity in vitro for compound PtL-Cl. After the initial
higher accumulation of Pt in cells, the efﬂux process becomes
most probably activated and the amount of total platinum inside
the cells gradually decreases. After 10 h of incubation, the uptake
and accumulation is starting to reach the highest concentration
at 18 h. After that time PtL-Cl appears to be excreted from the
cells and the accumulation of platinum after 24 h is relatively
higher than the initial accumulation. This study, however, do not
follow the same trend as described above (with 200 nmol/L active
concentration of PtL-Cl). Therefore, after a complete cell-cycle
a signiﬁcant accumulation of platinum has taken place, although
it cannot be correlated with the in vitro cytotoxicity data. This
behaviour can be explained by platinum removal or deactivation
with platinophiles inside the cells.
DNA cleavage studies
Agarose gel electrophoresis. The DNA cleaving ability of
PtL-Cl was investigated on reaction with fX174 supercoiled
phage DNA and relative mobility of the products on agarose gel.
PtL-Cl (20-200 mM) was incubated with DNA (20 mM in base
pairs) for 2 h at 37 ◦C in phosphate buffer (pH = 7.2), with or
without additives and reductant. On binding of an increasing
amount of PtL-Cl, the DNA shows signiﬁcant retardation in
mobility during electrophoresis (Fig. 4a; illustrated by the slower
migration of the bands), most likely caused by the increased
amount of adduct formation between the DNA and the metal
compound. The smear above the DNA is most likely indicative of
the disintegrationof the complexbetweenPtL-Cl andDNAduring
electrophoresis. Interestingly, little difference is observed in terms
of DNA cleavage between 0-20 mmol/L PtL-Cl, suggesting that
DNA cleavage only occurs after binding of multiple molecules of
metal compounds. This is supported by the observation that at
concentrations of 50 mM and higher extensive cleavage is seen,
with complete obliteration of the DNA at 200 mM, and that
hardly any nicked DNA (Form II, resulting from a single cleavage
event) and no linear DNA (Form III, double-strand cleavage) is
observed. During oxidative cleavage a more canonical cleavage
pattern was observed, with discrete bands and the expected
formation of Form II (Fig. 4b). This observation illustrates that
under these conditions nicking occurs on the intact (full-length)
fX174 DNA, while the absence of linear DNA highlights the lack
of double-strand cleavage. The added reductant (lane 7, 100 mM
ascorbic acid) or the radical scavenger (lane 9, 20 mM TEMPO)
do not affect the cleavage activity of PtL-Cl. With 200 mM
PtL-Cl, the DNA is completely digested. Thus, PtL-Cl behaves
differently from CuL-Cl, as the latter compound cleaves DNA
oxidatively and catalytically.26 With this concentration-dependent
experiment, however, “single-strand nicking” and “non-catalytic
(stoichiometric) cleavage” processes are difﬁcult to discriminate
with certainty.
The DNA cleavage reactions carried out with PtL-Cl are not
inhibited by the presence of various radical scavengers, that is,
NaN3, superoxide dismutase, DMSO, ethanol or D2O (Fig. 4b).
The use of distamycin highly inhibits the DNA cleavage and an
excess of NaCl does not inhibit the cleavage of DNA, and Form
II is still detected if the digestion is performed under argon,
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or reaction with exclusion of light. These results point to the
binding of PtL-Cl preferably in the minor groove as competed
by distamycin, and to non-diffusible radical pathways of DNA
cleavage.
High-resolution analysis of the cleavage process. To study the
non-oxidative cleavage phenomenon in more detail, high resolu-
tion DNA electrophoresis studies were performed, which allowed
for the separation of DNA fragments with single nucleotide
resolution (see below). This experiment was performed using a 5¢
radiolabelled double-stranded oligonucleotide, which was known
to produce a ladder of bands inherent to the fact that each coupling
step occurs with a 98-99% efﬁciency. The samples were then run on
a 15% denaturing gel, to allow identiﬁcation of DNA fragments
at single nucleotide resolution. Excitingly, while the control lane
clearly showed individual bands, on progressive degradation these
simply became fainter (more prominent for 200 mM DNA and
90 min incubation), eventually producing a continuous ‘smear’
(Fig. 5). This smearing is most likely the result of the cleavage
process and is not due to excessive background, as highlighted
by the intensity of the smear below the lowest nucleotide band
(15 nucleotide (nt), see bottom part of Fig. 5). PtL-Cl, therefore
attacks the DNA at multiple sites without any speciﬁcity like the
CuL-Cl. In fact CuL-Cl degrades the DNA in a very non-speciﬁc
manner, perhaps attacking the base and/or the sugar in multiple
positions (Fig. 5).
The mode of DNA cleavage activity (oxidative or hydrolytic)
towards pUC19 DNA by compound PtL-Cl and CuL-Cl was
investigated by transformation to E. coli competent cells. DNA
was linearised with a restriction enzyme (BamHI) (as a control),
or incubated with one of the compounds PtL-Cl or CuL-Cl.
Next, DNA was puriﬁed to remove the excess of metal com-
pounds, dissolved in water, and measured by the nano-drop
spectrophotometer to determine its concentration exactly. The
digestion mixture (5 ng) was then religated by T4 DNA ligase
and transformed to fresh competent cells of E. coli, to determine
the number of colony forming units (CFU). Comparison of the
transformation efﬁciencies of uncleaved pUC19 DNA with the
control experiment (BamHI digested and religated using DNA T4
ligase) showed that the ligation efﬁciency was close to 95%. Each
experiment was performed in triplicate, giving highly reproducible
results.
In Fig. 6 DNA digested with the restriction enzyme BamHI
is set to 100% religation efﬁciency, since restriction enzymes
generate intact 3¢- and 5¢- DNA ends that form a perfect template
for ligation. For the copper compound, the bar is somewhat
lower, indicating that the religation efﬁciency is reduced by just
over an order of magnitude, while the very low bar for the
Pt complex indicates approximately 1000-fold lower religation
efﬁciency compared to the restriction enzyme. The formation of
DNA ends that cannot be religated strongly suggests oxidative
cleavage, as this process will result in template ends that are
not recognized by the DNA ligase. The high religation efﬁciency
observed with DNA digested by CuL-Cl, shows that the oxidative
DNA cleavage efﬁciency of the CuL-Cl compound is lower than
that of PtL-Cl for the same amount of pUC19 DNA; however it
is still signiﬁcant. The fact that Pt(II) is unlikely to change valence
state in this process, points towards a phenoxyl-based process.
Circular dichroism
The DNA conformational changes induced by PtL-Cl, CuL-Cl
and Hpyramol were investigated by CD spectroscopy. Typical
Fig. 5 High-resolution analysis of the cleavage process induced by the compounds PtL-Cl and CuL-Cl. A 54 base pair double-stranded DNA fragment
was incubated with PtL-Cl for 0-150 min (left) and with CuL-Cl for 0-60 min (right). DNA size marker in nucleotides (nt) is shown on the left side of
the ﬁgure. Time (min) is indicated above the lanes. The probe was uniquely radiolabeled at the 5¢ end of the top strand. Smearing demonstrates multiple
cleavages of nucleotides.
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Fig. 6 Relative efﬁciency of cleavage activity of PtL-Cl and CuL-Cl on pUC19 DNA as (a) CFU per ng DNA and (b) relative CFU. Bam: DNA digested
with restriction enzyme BamHI; Cu: DNA cleaved with CuL-Cl and Pt: DNA cleaved with PtL-Cl. In all experiments the DNA was religated with T4
DNA ligase and then transformed to E. coli cells. CFU, colony forming units after transformation of E. coli cells with the DNA samples. Note that
Cu-cleaved DNA was restored much more efﬁciently by religation than Pt-cleaved DNA.
samples contained calf thymusDNA (CTDNA, 100 mMper base)
in the presence or absence of a metal compound (1 mM) in 10 mM
phosphate buffer (pH= 7.2). The ionic strength was kept constant
at 50 mM. Therefore, the R value remained constant at 0.1 for all
investigated compounds. The metal compounds do not exhibit
any CD in the chosen region of scan. The samples were incubated
at physiological temperature (37 ◦C) and the CD spectra were
recorded at certain time intervals (10 min intervals up to 60 min
and then 1 h intervals up to 12 h of incubation time). Cisplatin
was used as a reference under identical experimental conditions.
The changes observed in the native right-handed B-form DNA
on interaction with the compounds are shown in Fig. 7(a-d). The
panels 7a and 7b show the changes in the CD signal with short
and long incubation times, respectively, upon addition of PtL-Cl,
whereas the panels 7c and 7d show the changes in the CD signal
upon addition of CuL-Cl.
Fig. 7 Time-dependent conformational changes of right-handed DNA upon addition of PtL-Cl and CuL-Cl, in phosphate buffer (10 mM) at pH = 7.2
at 37 ◦C with R = 0.1. The panels (a) and (c) show the changes in the CD signal for PtL-Cl (1) and CuL-Cl (2), respectively, after a short reaction time.
The panels (b) and (d) show the changes in the CD signal after prolonged exposure of CT-DNA to PtL-Cl and CuL-Cl, respectively.
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The right handed B-DNA exhibits dramatic changes on its
characteristic positive and negative bands at 272 and 248 nm,
respectively, on interaction with of PtL-Cl and CuL-Cl [Fig. 7(a-
d)]. The changes started immediately after addition of the
compounds to the DNA solution and were observed till 12 h
after incubation. PtL-Cl induces a decrease in intensity for both
the positive (272 nm) and negative bands (248 nm). Also, new
negative (at 230 nm) and positive (at 310 nm) bandswere observed,
respectively, as part of the DNA structural degradation. The
decrease in positive band intensity indicates destabilization of
base-stacking and the decrease in the negative band intensity
points to loss in right-handed helicity.41 A similar behaviour
was observed for CuL-Cl. The changes observed immediately on
incubation of PtL-Cl and CuL-Cl reveal the DNA degradation
or unwinding due to strong interaction with the compounds. Also
the systematic decrease in the intensities of the bands is a proof for
a uniform, speciﬁc type of interaction for the PtL-Cl and CuL-Cl
with DNA, rather than a random mode of interaction. The total
loss of the DNA helicity and disruption of the base stacking can
be easily correlated to the DNA cleavage activity of PtL-Cl and
CuL-Cl.42 In a recent report41 the reduction in the intensity of the
positive band is reported to originate from interstrand crosslinks
to DNA (similar as transplatin). Indeed, the single chloride
can be hydrolysed forming a positively charged species that can
assist the ﬁrst electrostatic interaction of the metal compounds
with the DNA strand, followed by intercalation of the planar
ligand between the base pairs. Therefore, the combined effect of
intercalation and coordination is probable for both PtL-Cl and
CuL-Cl, to allow an effectiveDNA interaction and cause oxidative
damage.41,43
The CD spectral changes in DNA induced by the starting free
ligand, Hpyramol is shown in Fig. S3.† The concentrations of
DNA used were 50 mM (per base) and 500 mM ligand, with the
same R value of 0.1 as in the other samples. There is a slight
hyperchromic change in the positive maxima (278 nm) with a blue
shift of 2 nm. The reduction in intensity of the negative band
and its 1 nm red shift are also well marked. The appearance
of the new band at 230 nm is observed for both PtL-Cl and
CuL-Cl. In spite of the changes in intensity, the base-stacking
and right-handed helicity are retained, revealing that the ligand
only interacts, probably through intercalationwithDNA, but does
not induce DNA cleavage. Thus the CD spectral changes can be
directly correlated with the DNA-cleavage properties observed
with agarose gel electrophoresis.
The reference compound, cisplatin, is a classical example of
a metallodrug which binds to DNA by coordination. The CD
spectra in the presence of cisplatin remain mostly unperturbed
as a function of time (Fig. S3†). Initially the positive band
intensity slightly decreased and 2 nm red shift was observed
after 12 h of incubation. The base stacking remained stabilised
in time and the helicity of the right-handed B-DNA was found
slightly disturbed. The reduced intensity in the negative maximum
(248 nm) can be easily explained by the unwinding of the helix/or
by DNA kinking, which is caused by intrastrand and interstrand
crosslinks. Similar CD spectral changes were observed for all
above compounds, when the fX174 supercoiled phage DNA was
used for measurements instead of calf thymus DNA (data not
shown).
Spectro-electrochemical studies
Cyclic voltammetric scans of PtL-Cl at a Pt microdisk electrode
were conducted at room temperature in dry deaerated DMF. In
the anodic region, the cyclic voltammogram shows an irreversible
wave (O1) at Ep,a = +1.28 V vs Ag/AgCl for v = 100 mV s-1
(Fig. 8a). Awell-separated cathodic wave (R1) is observed atEp,c=
+0.25 V on the reverse scan. The reference compound CuL-Cl
exhibits a very similar anodic behaviour (Ep.a =+1.11 vsAg/AgCl
in MeCN), which was explained by axial solvent coordination
to oxidised [CuL-Cl]+.44 The anodic peak is attributed to the
oxidation of the phenolate part of the coordinated pyrimol ligand
to phenoxyl radical. The largely pyrimol (phenolate) localised
oxidation44 corresponds with the similar oxidation potentials
of PtL-Cl and CuL-Cl. The small Ep,a shift may have origin
in different kinetics of the coupled chemical reaction (solvent
coordination) and/or reﬂects the minor contribution of metal d
orbitals into the HOMO. A better insight should be obtained by
DFT calculations of PtL-Cl which, however, were considered as
out of scope of this work. The phenolate oxidation in PtL-Cl
can also be compared with the oxidation of the dehydrogenated
Hpyrimol ligand in DMF (Fig. 8b), which is also irreversible and
slightly positively shifted to Ep,a = +1.35 V vs Ag/AgCl. In the
latter case, however, the coupled chemical reaction might have a
different origin (e.g., deprotonation).
Fig. 8 Cyclic voltammograms of 10-3 M PtL-Cl (a) and the free ligand, Hpyrimol (b) in the anodic region. Conditions: freshly polished Pt working
electrode (apparent surface area of 0.312 cm2), v = 100 mV s-1, DMF/10-1 M Bu4NPF6, room temperature.
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The UV-Vis spectrum of PtL-Cl in dry DMF shows prominent
absorptionbands at 620, 425 and310nm.These bands are replaced
during the oxidation at the O1 electrode potential (+1.28 V vs
Ag/AgCl) by new absorptions at 260 (sh) and 380 (sh) nm and
a poorly resolved absorption between 400–600 nm (Fig. 9). The
visible absorption of the oxidised species reﬂects the presence of
the phenoxyl radical ligand (L∑) derived frompyrimol. TheUV-Vis
spectrum of short-lived free L∑ (shoulder at ca. 430 nm)45 is shown
in the Supporting Information (Fig. S4†). For oxidised [CuL∑-Cl]+,
the corresponding electronic transitions between 400-500 nmwere
shown by TD-DFT to have a mixed intraligand (L∑) and charge-
transfer (Cu-to-L∑) character.44 The involvement of the transition
metal centre in the visible electronic excitation may explain the
low-energy shift of the absorption to 500-600 nm for [PtL∑-Cl]+
(Fig. 9) compared to CuL-Cl.
Fig. 9 UV-Vis spectral changes accompanying the rapid oxidation of
PtL-Cl at the electrode potential O1 to a phenoxyl radical species in DMF
at room temperature, using an OTTLE cell.
Differently from fairly stable [CuL∑-Cl]+ that could be reduced
back on the time scale of min to largely recover the neutral parent
compound,44 the oxidised [PtL∑-Cl]+ species is more reactive at
room temperature, as concluded from a constant decay of its
absorption in the OTTLE cell prior to the reverse reduction at
the cathodic wave R1. The apparent difference in the relative
stability of the phenoxyl radical complexes may explain the higher
(catalytic) activity of CuL-Cl towards the DNA substrate, as
described in this work. The species [CuL∑-Cl]+ was shown by
cyclic voltammetry to bind reversibly a solvent molecule, probably
at the axial position.44 In strictly square planar [PtL∑-Cl]+ the
expected strong trans effect labilises the Pt-Cl bond, causing
dissociation of the chloride ligand and solvent coordination, being
probably coupled to further reactivity. The existence of the solvent-
substituted species [Pt(pyrimol)(Sv)]+ (Sv = DMF or DMSO)
formed during the reaction of PtL-Cl with model DNA bases in
these donor solvents, as revealed by ESI-MS (see below), supports
strongly this argumentation.
Reactions with DNA model bases
9-Ethylguanine. The reaction between PtL-Cl and 9-EtG,
typically in the molar ratios 1:1 and 1:4, was monitored by 1H and
195Pt NMR spectroscopy. 9-EtG was dissolved in DMSO-d6 and
spectra were recorded at physiological temperature (37 ◦C). Also
the time-dependent ESI-MS studies were performed to determine
the relative formation rate of the adduct. The reaction mixture
showed the presence of unreacted reagents (PtL-Cl and 9-EtG)
and very small peaks arising from themono-adduct independently
of the molar excess of the model base. The time-dependent serial
spectra (1HNMR) showed only small changes (Fig. 10). However,
a new peak in 195Pt NMR at -2405 ppm was clearly observed after
48 h, which can be assigned to a PtN3O moiety.
Fig. 10 Stacked 1H NMR spectra of PtL-Cl in presence of 9-EtG (1:1) in
DMSO-d6 at 37 ◦C.
The ESI-MS also proves the gradual evolution of the adduct,
[Pt(pyrimol)(9-EtG)]Cl at m/z = 620.96. In the reaction mixture
the species present can be assigned as (a) [Pt(pyrimol)( dmso)]+;
m/z = 483.91, (b) [Pt(pyrimol)(9-EtG)]+; m/z = 585.86; (c)
[Pt(pyrimol)(9-EtG)(dmso)]+; m/z = 662.79, (d) 9-EtG; m/z =
178.92 and (e) 9-EtG+DMSO; m/z = 253.99. The platinum-
containing species show the typical Pt isotopic pattern. The
major component of the reaction mixture is the solvated product,
[Pt(pyrimol)(dmso)]+. The reaction is not immediate, but the
appearance of this mono-adduct was observed by ESI-MS (see
Fig. S5†) and NMR only after 24 h.
5¢-Guanosine monophosphate. PtL-Cl was allowed to react
with this model base in different molar ratios (namely 1:1 and 1:4)
in a solventmixture ofDMSO-d6 andD2Oat 37 ◦C.The changes in
NMR and ESI-MS spectra were followed in certain time intervals.
The poor solubility of PtL-Cl in aqueous solvent and no solubility
of GMP in organic solvent, limits the use of PtL-Cl at high
concentrations. The clear progress of 1H NMR changes is shown
in stacked spectra (Fig. 11). The 195Pt NMR revealed a new signal
at -2820 ppm after 24 h (N2OS coordination environment around
Pt)39,40 quite changed from the peak from the starting compound
PtL-Cl at -2319 ppm (in DMSO-d6+D2O). Results of a time-
dependent ESI-MS study performed in DMF (shown in Fig. S6)
document the presence of a mixture of adducts assigned (a)
[Pt(pyrimol)(dmf)]+ (i.e., solvolysis in presence of DMF); m/z =
479.87, (b) [Pt(pyrimol)]+ +3 CH3OH (eluting solvent); m/z =
537.86 (major), (c) [Pt(pyrimol)]+ + 2 DMF; m/z = 552.82, (d)
[Pt(pyrimol)(GMP)]; m/z = 842.97, (e) [Pt(pyrimol)(GMP)] +
DMF; m/z= 921.71. Therefore the mono-substituted adduct can
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Fig. 11 Time-dependent changes in 1H NMR spectra of PtL-Cl upon
addition of 5¢-GMP inDMSO-d6+D2Oat 37 ◦C.The arrows showgradual
changes (rise of a new peak [up] or decrease of a peak [down] with time).
be identiﬁed, but the solvent-coordinated species is the major one
and is not easily substituted by model base.
Interaction with d(GTCGAC)2
The interaction of PtL-Cl with the self complementary oligonu-
cleotide d(GTCGAC)246 was carried out at different temperatures
ranging from 4-47 ◦C to obtain a slow or fast proton exchange
rather than an intermediate exchange. 1H NMR spectra were
recorded in 90% H2O and 10% D2O to follow any changes in
the amine/imine protons of the oligonucleotide. The variable
temperature 1-D, 1H NMR experiments show that at 17 ◦C
(Fig. S7) and 27 ◦C (Fig. S8)† fast exchanges were observed and
the Tables 4 and 5 clearly describes the proton shifts (in ppm) for
the PtL-Cl (free) and after interacting with the oligonucleotide at
17 ◦C and 27 ◦C. The used numbering of the protons is depicted in
the insert with the 1H NMR spectra in Fig. S8.† The assignments
were based on 2D DQF-COSY, through bond interactions at
27 ◦C; they were done for the pure PtL-Cl compound and for
PtL-Cl after interaction with the oligonucleotide at 27 ◦C (Figs.
S9 and S10).† In general, the bound compound shows large shifts
of the ligand proton signals, especially in the phenolate part (3H
and 4H) compared to the less affected methylene protons (signal
9H) and medium shifted pyridine ring proton signals 11H to 14H,
(Figs. S8 and S11).† The totally decayed appearance of signal
Table 4 1H NMR signals (d in ppm) of PtL-Cl before and after the
interaction with oligonucleotide
PtL-Cl–protons
No
oligonucleotide
In the presence of
d(GTCGAC)2 at
27 ◦C
In the presence of
d(GTCGAC)2 at
17 ◦C
3 (d) 6.89 8.22 8.23
4 (d) 6.50 7.72 7.71
6 (s) 8.77 7.58 7.60
9 (s) 7.20 7.34 7.38
11 (d) 7.64 7.96 7.90
12 (t) 8.12 8.17 8.16
13 (t) 7.64 7.43 7.41
14 (d) 8.55 7.98 7.97
Table 5 1H NMR signals (d in ppm) of oligonucleotide before and after
interaction with PtL-Cl
d(GTCGAC)2 - protons
Free
(no PtL-Cl)
With PtL-Cl
at 27 ◦C
With PtL-Cl
at 17 ◦C
8H of G1 7.946 8.016 8.031
8H of G4 7.458 7.982 8.031
8H of A5 7.921 7.982 8.014
2H of A5 8.132 8.053 8.052
5H of C3 5.589 6.523 6.520
5H of C6 5.262 6.940 6.963
6H of C3 7.446 6.725 6.712
6H of C6 7.257 7.114 7.124
6H of T2 7.496 7.535 7.538
2¢ 1.8–3.0 — —
4¢;5¢ 3.7–4.5 — —
3¢ 4.4–5.2 — —
1¢ 5.3–6.3 — —
11 and the approximately 1.5 ppm downﬁeld shifts observed for
the signals 3H and 4H, clearly reveal the intercalating mode of
interaction for the PtL-Cl through the pyrimol ligand between
the nucleobases. Further, the shifts of the oligonucleotide proton
signals can be observed for all the base protons, but the highest
is with cytosine (C3H5, C3H6) and guanine (G4H8) protons in
the central position of the oligonucleotide. Again, the proton
assignment was achieved by comparing the 2-D DQF-COSY
spectrum of the free oligonucleotide and the 2-D DQF-COSY
spectrum of d(GTCGAC)2 interacting with PtL-Cl at 27 ◦C. The
sugar protons could not be followed individually, due to broad and
merged signals after interaction with the Pt compound. The same
kind of broadened signals were observed for the amino/imino
protons, immediately after interacting with PtL-Cl, making it
difﬁcult to follow the signal in time, also in 2-D experiments.
Based on the assignments, the NOESY spectrum at 27 ◦C was
also analysed to detect any through space interactions between
the oligonucleotide and PtL-Cl (within 4 A˚, Fig. S12).† The cross
peaks observed between (i) the ligand proton 9 to C3H5/C6H5;
(ii) 6 to the 1¢ sugar protons and (iii) 13 the 3¢ sugar protons,
are important to reveal that the compound tends to interact in
the minor groove of the oligonucleotide at the fast exchange
rate.47 That is from the C3 to the C6 region of d(GTCGAC)2,
which is also obvious from the proton shifts associated with the
corresponding bases. For the small molecules like Cu(phen)2+ the
minor groove binding is suggested for a compact and closer DNA
interaction. Thus the simple, planar PtL-Cl could also be expected
to interact initially withDNA in theminor groove. The unassigned
peaks observed in the 1-D spectra (data not shown) after 8 h
of interaction can be assumed as arising from the cleaved DNA
(sugars/bases), which again supports a non-speciﬁcDNAcleavage
event occurring on interaction with PtL-Cl.
Conclusions
A novel platinum compound was synthesised and characterised
in detail by NMR and X-ray analysis. The Pt(II) ion is in a
square-planar coordination environment with the ligand having a
tripodal (N,N,O) chelating motif. The ligand precursor Hpyramol
was found to dehydrogenate and form the pyrimol anion that
binds ﬁrmly to Pt(II). This compound induces single-strand
scission of supercoiled DNA, just like the previously reported26
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analogue CuL-Cl, albeit in stoichiometric concentrations rather
than catalytic amounts. Both compounds show high to modest
in vitro cytotoxic properties against various cancer cell lines. The
cancer cell-growth inhibition ability appears to be strongly time-
dependent and selective towards some cell lines. The cytotoxic
activity induced by CuL-Cl may be explained by catalytic DNA
cleavage, which results in irreparable damage, different cellular
processing and the bioavailability inside the cells. The compara-
tively low activity of PtL-Cl indicates reversible DNA damage,
facile repair mechanism, higher stability of solvated intermediate
and non-availability of the active species in intracellular medium.
To correlate the DNA cleavage properties, in vitro cytotoxicity
and the DNA structural changes, several techniques were used to
provide mechanistic insights.
The spectro-electrochemical studies of PtL-Cl in comparison
with CuL-Cl and free Hpyrimol provide supportive evidence for
the formation of a phenoxyl radical and its likely involvement
in oxidative DNA-cleavage. The structural changes of the DNA
were followed by circular dichroism and gel mobility studies
and the observed DNA degradation by PtL-Cl was further
analysed in detail by high-resolution gel electrophoresis. These
experiments not only indicated extensive DNA degradation, but
also demonstrated that PtL-Cl cleaves nucleotides simultaneously
or sequentially at multiple positions. The reactions of PtL-Cl
with DNA model bases (9-ethylguanine and 5¢-GMP; 1:1) at
physiological temperature exhibit the slow formation of mono-
adducts with chloride substitution via solvolysis. Our studies also
highlighted that PtL-Cl primarily interacts with the minor groove
of the DNA, in contrast to cisplatin which preferentially binds to
the major groove.
The title compound PtL-Cl induces signiﬁcant damage to iso-
lated DNA under experimental in vitro conditions of biophysical
studies; however, DNA damage inside the cancer cells might
be easily reparable. Being a monofunctional compound, PtL-Cl
induces comparatively lower cytotoxicity than cisplatin in a panel
of cell lines. The mono-adduct formed on the DNA helix in the
minor groove by small PtL-Cl, is unable to widen the minor
groove. As a result the typical ‘kink’ of cisplatin interaction is
not induced and the DNA degradation is eventually repaired by
the cell machinery.
Thus the DNA-targeting monofunctional platinum compound
possessing dual intercalation-coordination property in fact acts as
minor-groove binder and simultaneously overcomes the resistance.
The present work, including all the mechanistic studies, strongly
suggests that a controlled modiﬁcation, could lead to new,
potential antitumour compounds that can survive the repair
mechanism and induce facile apoptosis.
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